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ABSTRACT 
Objective: In this study it is proposed to compare the effect of three different bariatric metabolic procedures such as Laparoscopic Roux-en-Y 
gastric bypass (RYGB) Laparoscopic Mini gastric bypass (MGB) and Laparoscopic sleeve gastrectomy (SG) on diabetes remission and reduction in 
co-morbidities. 
Methods: A retrospective analysis of prospectively collected data base of three bariatric metabolic surgery groups were screened from the year 
2010-2014 at the study centre for patients satisfying the inclusion criteria. Three follow up data at an interval of three months and a base line value 
for all the three groups were collected. Outcome measure the percentage of patients achieved diabetes remission according to American Diabetes 
Association Criteria (ADA)/International Diabetic Federation (IDF) criteria i.e. Glycosylated haemoglobin (HbA1c)<6 % or<6.5 % without active 
pharmacological therapy at least I year post surgically and percentage patients lost>60% excess body weight. Secondary outcome includes the 
percentage reduction in cardiovascular risk factors, changes in medication associated with diabetes and cardiovascular diseases and immediate and 
later complications of the three different procedures of surgery. All calculations were performed using SPSS Version 18 statistical software. 
Descriptive statistics included are calculation of mean and standard deviation. Chi–square test and two factor ANOVA for comparison of means 
between groups under study. 
Results: All the three surgical groups were comparable in reducing the excess body weight, HbA1c and cardiovascular complications. Highest 
response to weight reduction at 9 to 12 mo was reported from MGB group which was statistically significant between groups. Percentage of patients 
achieved diabetes remission according to ADA/IDF criteria was not statistically significant between groups but within group it was highly 
significant. Hypercholestremia reduction between MGB and GB was highly significant P value is **0.002. The lowest percentage of complications 
after surgery was reported by MGB group followed by SG. 
Conclusion: MGB relatively a new surgical procedure seems to be a better option for treating, obesity, uncontrolled diabetes and related co-
morbidities. 
Keywords: Bariatric metabolic surgery, Glycosylated hemoglobin, Obesity, Type 2DM Laparoscopic Roux-en-Y gastric bypass, Laparoscopic mini 
gastric bypass, Laparoscopic sleeve gastrectomy, Essential weight loss % (EWL%). 
 
INTRODUCTION 
In 2013, an estimated 382 million people had type 2DM and this 
number predicted to rise to 592 million by 2035 according to 
international diabetic federation [1]. Majority of patients with Type 
2DM are obese showing a close relationship between obesity and 
Type 2DM [2]. Obesity increases morbidity and associated 
complications and reduces life expectancy. The risk may be 
diminished if hyperglycaemia and overweight is optimized to a 
modest level. In the look AHEAD(Action for Health in Diabetes) trial, 
intensive life style intervention caused significant weight loss and 
improvement in glycosylated haemoglobin (HbA1c) level and was 
more effective than routine life style advice in achieving diabetes 
remission [3]. But the effect reduced from 12% at one year to 7% at 
four years. The weight loss associated with intensive life style 
modifications and oral medication are moderate and effects will not 
last for the long period of time. Bariatric surgery initially a weight 
loss surgery is becoming a most effective treatment method for the 
obese and diabetic patients [4]. Several factors make type 2DM 
challenging to treat in obese and diabetic Patients. Patients who lost 
weight via behavioural changes tends to regain the weight. Anti-
diabetic drugs of newer classes are available but most patients fail to 
achieve the set goal. A variety of weight loss surgical procedures are 
available such as RYGB,, MGB and SG but it is difficult to say which is 
the most effective surgical procedure based on the patient 
characteristics [5]. Weight loss induced by bariatric surgery is a 
major factor of diabetes improvement but in several studies, it is 
reported that improvement in diabetes status occurred even before 
significant weight loss was reported. Early post surgical 
improvement suggests involvement of various intestinal gut 
hormones [6]. These observations suggest a difference in efficacies 
between surgical procedures depending up on the mode of surgery 
(restrictive, malabsorptive or combined) and patients with relatively 
different anthropometric characters as well as other coexisting illness. 
The aim of the present study was to evaluate the efficacy of these three 
procedures to induce weight reduction, remission or amelioration of 
diabetes and related co morbidities. 
MATERIALS AND METHODS 
The retrospective observational study was conducted at the 
bariatric and metabolic surgery department of Moulana hospital 
Perinthalmanna after receiving the institutional ethical committee 
approval. The study population who had undergone any of the three 
surgical procedures namely RYGB, SG or MGB with an age of 25–60 y, 
body mass index (BMI)>30 kg/m2 with type 2DM for more than 2 y 
and HbA1c not less than 7.5%, at the base level with a minimum 
follow up of 18 mo, with co morbidities preferably, cardiovascular 
risk factors (hypertension systolic above 180 and diastolic above 85, 
total cholesterol above 180 mg/dl) were selected for the study. 
Initially there were 180 patients, 60 from each group, but lack of 
follow-up details only 176 patients included in the final analysis. The 
data were collected for a follow up period of 12 mo. The reduction in 
BMI and percentage of EWL, reduction in HbA1c, immediate (within 
30 d reported) and late surgical complications were noted. The 
patient group was matched for age, gender, BMI andHbA1c, total 
cholesterol, and distribution of other co morbidities. Diagnosis of 
type 2 DM was made according to American Diabetes Association 
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guidelines and surgery followed fulfilment of the Consensus in Asia–
Pacific2005 criteria [7]. The initial data collected at baseline 
included height, weight, HbA1c, total cholesterol, cardiovascular 
medications, and all other baseline laboratory values. Similarly 
follow-up data were collected at three months interval which 
included changes in BMI, weight loss, HbA1c, lab values, medication 
use pattern, immediate and late complications of the three surgical 
procedures change in lab values from baseline were followed in the 
three groups. Weight loss is reported as the mean percentage of 
excess weight loss which is the standard procedure in the bariatric 
procedures. 
Outcome measure 
Primary outcome was the difference in the percentage of patients 
achieved complete remission<6%, or partial remission<6.5% 
without active pharmacological therapy at least one year post 
surgically according to ADA/IDF criteria. Secondary outcome includes, 
post surgical complication of the three procedures, percentage of 
patients lost more than 60% excess body weight from the baseline 
with percentage reduction in anti-diabetic and cardiovascular drugs 
and reduction in cardiovascular risk factors. 
Statistics  
Data collected for the study were tabulated, and the result was 
analyzed using SPSS (Version 18.0, SPSS Inc, Chicago, III). Descriptive 
statistics included the calculation of mean and standard deviation. Chi–
square test and two factor ANOVA for comparison of parameters 
between groups under study. The effects were found to be significant 
to the least significant difference (LSD) at 5% level of significance to 
separate out significant parameters. If found significant in ANOVA, a 
Post Hoc test namely Boneferroni test was applied to separate out the 
independent difference between individual groups. 
RESULTS AND DISCUSSION  
A total of 176 patients, all diagnosed with type 2DM at base line, of 
which 47.7% males and 52.3% females were selected from three 
different surgical groups namely RYGB (N=60), MGB (N=57), and SG 
(N=59) screened from the electronic bariatric data base of the 
Moulana hospital who satisfies the inclusion criteria. The mean 
value of pre-surgical HbA1c, metformin dose, duration of diabetes in 
the entire group showed uniformity in distribution. Age, BMI insulin 
dose and total cholesterol had difference at base line mean values 
(Table1). After surgical intervention (table 2) a significant and 
consistent reduction in BMI, HbA1C values was observed relative to 
the base line values in all the groups. In MGB the mean baseline value 
for BMI changed from 41.832±9.332 to 28.504±8.275, and in RYGB 
47.4938±8.00 to 32.84±6.80 and in SG 40.474±4.87 to31.28±3.758 
and HbA1c there was change in MGB 8.405±1.441 to 5.993±0.88 and 
in RYGB 8.1681±0.366 to 5.898±0.717 and in SG 8.306±0.957 to 
6.014±0.7740. In total cholesterol there was change in MGB from 
192.313±7.360 to 176.221±37.718 and in RYGB 212.07±74.932 to 
161.95±28.122 and in SG 207.926±5.399 to164.140±32.643. The 
mean value of insulin dose shows difference at the baseline to post 
intervention at one year MGB 60.556±9.668 to 0 RYGB 48.17±24.67 to 
0 and in SG 33.90±23.098 to 0. For all the three surgical groups at 
one year insulin was stopped. Oral hypoglycaemic agents were 
significantly reduced after one year in all groups in MGB 
956.05±571.036 to 279.53±350 RYGB 1109.325±55.573 to 
279.53±338 and in SG 1082.765±53.819 to232.92±325. In all the 
groups’ reduction of insulin dose and oral hypoglycaemic agents 
were highly significant between baseline values and post 
interventional values. Between groups reduction was uniform hence 
there is no statistical significance for insulin and oral hypogycemic 
agents (OHA) reduction in the three groups [8, 9]. 
 
Table 1: Baseline characteristics of patients in the three study group 
Character MGB (32.4%) SG (33.5%) RYGB (34.4%) 
No of patients  N=57 N=59 N=60 
Male%  28(49.1) 22(37.3) 34(56.7) 
Female% 29(50.9) 37(62.7) 26(43.3) 
Age in years 40.35±9.819 32.32±11.729 36.909±9.28 
Duration DM 7.675±.12 6.1184±.18 7.625±.560 
Excess Weight 45.859±25.576 44.144±13.6735 45.968±8 
BMI kg/m2 41.832±9.332 40.474±4.876 47.4938±8.00 
HbA1c 8.405±1.441 8.036±0.9571 8.1681±0.366 
Insulin I U 60.556±9.668 33.90+23.098 48.17+24.67 
Metformin mg 956.05+571.036 1082.765±53.819 1109.325±55.573 
 chol-mg/dL 192.313±7.360 207.926±5.399 212.07±74.932 
N=number of participants, MGB–mini gastric bypass SG-sleev gastrectomy, RYGB–Roux-en-y-gastric bypass. BMI-body mass index insulinIU dose/day, 
metformin milligram/day, chol-cholesterol. 
 
Table 2: Anova for base line Pre-interventional 
Characteristics Df F P value 
Age 2 8.787 **<0.001 
Duration 2 8.345 >0.05 
Bmi 2 18.448 **<0.001 
Excess weight 2 8.326.  *<0.05 
Hba1c 2 1.254 0.288 
Insulin IU 2 5.268 **<0.006 
Metformin 2 1.218 0.298 
Total cholesterol 2 6.058 *0.003 
*Pvalue<.05(significant), p**<.01(more significant),***pvalue.001(highly significant. 
 
The three surgical groups at one year showed>60% diabetes 
remission according to ADA criteria i.e. HbA1c ≤6 % without glucose 
lowering medications. More than 20% showed reduction in 
HbA1c<6.5% without glucose lowering medication and ≤15% 
showedHbA1c ≥ 6.5%. (fig. 1).  
Fig. 1: X-axis showing different HbA1c level in three surgical group 
namely SG RYGB, MGB at 9-12 mo, Y axis showing % of population 
achieving the different HbA1c level HbA1c<6%,between 6 to 6.5% 
(without pharmacological therapy) and HbA1c>6.5% with 
medications at one year. Remission of diabetes HbA1c<6% occurred 
67% in MGB 66.7% in GB and 62% in SG group. HbA1c between 6-
6.5% reported 25% in MGB, 21.0 % in RY GB and 22.7% in SG 
group,>6.5% HbA1c was reported 12% MGB, 11.4% RYGB and>15% 
in SG. The remisson/reduction in diabetes occurred after surgery, in 
all three group was significant. Post hoc anova between groups 
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showed no statistical significance. In our study MGB and RYGB 
showed highest remission of diabetes. Several studies reports that 
no statistical significance between different surgical procedures in 
achieving diabetes remission [10, 11]. 
 
 
Fig. 1: HbA1c % in the three groups at one year 
 
Excess weight loss at three different intervals  
At base line following are the excess weight in the 3 interventional 
surgical groups RYGB (45.4938±21.29), SG (40.474±4.876), and MGB 
(40.7329±9.332) (Table1). Anova at base line for the entire group 
was significant the p value showed was*<0.05 (table 2).  
 
 
Fig. 2: Excess weight loss at three different intervals. 
 
Fig. 2 shows excess weight loss at three different intervals during 
the follow up period. All the three groups showed weight reduction 
after surgery which was comparable among groups. Initially at third 
month and sixth weight loss reported in SG was more compared to 
the other two groups. During the next follow-ups MGB and RYGB 
showed better reduction compared to SG (fig. 2). Towards the end 
weight loss was more in MGB group and p value is **0.001 
 
 
Fig. 3 BMI reduction during follow-ups 
 
Fig. 3 showing changes in body mass index during the follow-ups. SG 
and RYGB showing sharp reduction whereas MGB showing more 
sustained and gradual reduction 
Table 4 Shows post hoc-anova for significance. From the table it is 
found that, BMI and total cholesterol, having high statistical 
significance P value<**0.001and<**0.002 respectively. The 
significance between groups were analyzed using Boneferroni test 
and it is found that there was a statistical significance between MGB 
versus SG in BMI and P value is *.035 and RYGB versus SG p**0.002 
and in total cholesterol there was significance between MGB versus 
GB P value is **0.002. 
Table 5 shows the reduction in number of cardiovascular risk 
factors. There is significant reduction between pre and post 
conditions p value is *0.05 Highest reduction in hypertension and 
hyper cholesteremia were shown by RYGB group between group 
there was significance for hypercholestremia and P value is**0.002. 
Ikramuddin et. al randomized 120 patients to receive RYGB of 12 mo 
of follow-up. The primary treatment goal was a composite of 
HbA1c<7%, LDL cholesterol<100 mg/dl, and systolic blood 
pressure<130 mm Hg, and was reached by 49% of those receiving 
surgery. 
In the entire group there was reduction in cardiovascular risk 
factors from base line to post intervention MGB 78 % reduction 
reported SG 73%reduction and RYGB 83.4% reported 
 
Table 3: Post-Interventional value with mean and standard deviation 
Characteristics Group N Mean Sd 
Bmi post MGB 57 28.504± 8.275 
Bmi post SG 59 31.28± 3.758 
Bmi post RYGB 60 32.84± 6.800 
Hba1c % post MGB 57 5.99 3± 0.880 
Hba1c % post SG 59 6.014± 0.774 
Hba1c % post RYGB 60 5.898± 0.717 
Metformin post MGB 55 279.53± 350 
Metformin post SG 59 232.92± 325 
Metformin post RYGB 60 258.33± 338 
Excess weight loss MGB 57 29.45± 7.380 
Excess weight loss SG 59 23.15±  6.413 
Excess weight loss RYGB 60 40.93± 14.601 
Total cholesterol post MGB 51 176.221± 37.718 
Total cholesterol post SG 56 164.14± 32.643 
Total cholesterol post RYGB 60 161.95± 28.122 
Table 3 shows post interventional values with mean and standard deviations for the follow up criteria. Since Insulin was stopped in all the groups at 
9-12 mo, post interventional value for insulin is not included. 
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Table 4: Post hoc-anova for significance of the follow ups 
Parameters Df F Significance 
BMI-post 2 6.891 **0.001 
Insulin dose 2 0.357  0.598 
Metformin dose 2 0.111  0.740 
HbA1c% 2 1.254  0.288 
Total cholesterol 2 6.058  **0.002 
Excess weight loss 2 6.321 >0.05 
Df–degrees of freedom, F statistics factor  
 
Table 5: Pre and Post cardio vascular risk factors (Secondary end points) 



















Cardiac medicine Pre N=20(35%) Pre N=17(28%) Pre N=25 (41%) *<0.05 
 Post N=5(9%) Post N=5(9%)  Post N=6 (10%)  NS 
HTN=Systolic BP>140 mmHg Diastolic= BP>95 mmHg Hypercholestremia= Total cholesterol>180 mg/dL, CAD=Coronary artery diseases, 
cardiovascular medicine=Anti hypertensives+Antilipedemic+Anticoagulants 
 
Table 6: Immediate post surgical complications 
Parameter MGB SG RYGB 
Leak 2(2.86) 0(0%) 6(9.3%) 
Pneumonitis 3(5.3%) 14(24%) 8(13.6) 
Pulmonary embolism 0(0%) 1(1.6) 1(1.5) 
 
Table 7: Chi-square test for significance of complications after surgery 
Parameter  SS Df P value 2 sided 
Bleeding 5.901 2 0.52 
Leak  4.887 2 0.087 
Pneumonitis 6.372 2 0.041 
Pulmonary embolism 2.100 2 0.350 
ss-sum squares, df-degrees of freedom, ms-mean square*p value<.05 (significant) The chi square test shows no statistical significance between groups. 
 
Table 6 shows immediate post surgical complications. RYGB group 
showing highest surgical complications after surgery followed by SG 
group. Lowest number of complications reported in MGB group. 
DISCUSSION 
Metabolic surgery not only brings about weight loss but has effects on 
gut hormones and beneficial in the management of diabetes and 
related co-morbidities. Wight loss obtained after surgery is associated 
with highly significant reduction in cardiovascular risk factors [12]. 
The three procedures were successful and weight reduction was 
impressive in all groups, patients showed remarkable improvement in 
their diabetic status ie more than 60% of patients showed complete 
remission of type2 DM while more than 90% showed a significant 
decrease in their insulin or OHA demand. The highest response to the 
treatment with the lowest number of complications was shown by 
MGB group. .Similar result was shown by Milone M et al.[13]. A 
systematic review of bariatric literature showed that SG and MGB are 
safe alternative to RYGB. A report from Lee et al. Suggest that duodenal 
exclusion may play the role in diabetes remission other than weight 
loss [14, 15]. The new therapeutic algorithms of type 2DM suggest an 
earlier intervention for the remission of type 2DM. However, the 
choice of surgical procedure to be used remains an unresolved 
question. The choice of surgical procedure remains open according to 
IDF/ADA recommendations.  
CONCLUSION 
Type 2 Diabetes is no longer an uncontrollable disease. A return to 
normal level of glucose is possible with metabolic surgery. The three 
surgical procedures were comparable in reducing the excess body 
weight, HbA1c and cardio vascular complications in accordance with 
ADA/IDF criteria. Highest response to weight reduction was shown by 
MGB which was statistically significant between groups. Reduction in 
comorbidities, less surgical complication was reported in MGB 
compared to RYGB and SG. These findings can potentially influence the 
physicians to choose the right type of bariatric and metabolic surgery. 
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